三个皮匠报告—— 严选型全行业研究报告分享下载平台,您的专属行业智库!
欢迎来到三个皮匠报告!
登录
帮助中心
首页
最新
研搜
BETA
合集
英文
会议
数据
财报库
政策库
自研报告
入驻
您的当前位置:
首页
>
行业数据
>
FDA获批药物中FIC(FirstinClass)药物占比
FDA获批药物中FIC(FirstinClass)药物占比
行业数据
下载Excel
下载图片
原图定位
图片属性
图片格式:PNG
图片大小:350KB
图片尺寸:1736*795
同报告图片
/
4
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
所属报告:
百诚医药-公司首次覆盖报告:综合型CRO 加速转型权益分成业务厚积薄发-230811(30页).pdf
打包全文图表
相关数据
到2040年美国FDA批准的中国原创新药占比
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
收藏
行业数据
2026-06-11
原图定位
查看详情
美国FDA各年度批准NME药物与生物药数量
收藏
行业数据
2026-05-25
原图定位
查看详情
美国FDA药物评价与研究中心受理的IND申请
收藏
行业数据
2026-04-08
原图定位
查看详情
图表11FDA获批KRASG12C抑制剂的全球销售额(百万美元)
收藏
行业数据
2026-02-25
原图定位
查看详情
图 26 美国食品和药物管理局(FDA)在2020年开始实施RACE法案,以确保更多癌症药物试验包括儿童人群
收藏
行业数据
2026-02-13
原图定位
查看详情
**TABLE 5. FDA-approved Immunotherapeutics to Treat Pediatric Cancers (2015–2025)**
收藏
行业数据
2026-02-13
原图定位
查看详情
**TABLE 4 FDA-approved Molecularly Targeted Therapies to Treat Pediatric Cancers (2015–2025)**
收藏
行业数据
2026-02-13
原图定位
查看详情
表 5 FDA批准的免疫治疗药物用于治疗儿科癌症(2015–2025)
收藏
行业数据
2026-02-13
原图定位
查看详情
Figure 2 FDA-approved therapeutics with CDx, including novel oncological therapies (1997-2024)
收藏
行业数据
2026-02-13
原图定位
查看详情
表4 FDA批准的分子靶向疗法用于治疗儿童癌症(2015–2025)
收藏
行业数据
2026-02-13
原图定位
查看详情
2018-2024年FDA批准的创新抗体药物分类(个)
fCDliIbnsbsgICB8IOaVsOmHj++8iOS4qu+8iSB8IOWNoOavlCAgIHwKfCAtLS0tLS0gfCAtLS0tLS0tLS0tIHwgLS0tLS0tIHwKfCDltYzlkIjkvZMgfCAzICAgICAgICAgIHwgNC42JSAgIHwKfCDlhajkurrmupAgfCAyMiAgICAgICAgIHwgMzMuOCUgIHwKfCDkurrmupDljJYgfCA0MCAgICAgICAgIHwgNjEuNSUgIHwKCui1hOaWmeadpea6kO+8muWFrOWPuOaLm+iCoeS5pu+8jOW8l+iLpeaWr+eJueaymeWIqeaWh++8jOWbveazsOa1t+mAmuivgeWIuOeglOeptg==
收藏
行业数据
2026-01-27
原图定位
查看详情
2018-2024年FDA批准的全人源抗体制备技术分
fCDmioDmnK/nsbvliKsgICAgICAgfCDmlbDph4/vvIjkuKrvvIkgfAp8LS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS18Cnwg6L2s5Z+65Zug5bCP6byg5oqA5pyvIHwgOSAgICAgICAgICB8Cnwg5Zms6I+M5L2T5bGV56S65oqA5pyvIHwgNyAgICAgICAgICB8Cnwg5YW25a6D5oqA5pyvICAgICAgIHwgNiAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrlhazlj7jmi5vogqHkuabvvIzlvJfoi6Xmlq/nibnmspnliKnmlofvvIzlm73ms7DmtbfpgJror4HliLjnoJTnqbY=
收藏
行业数据
2026-01-27
原图定位
查看详情
FDA拟禁用合成色素种类在欧盟和中国使用情况
fCDlsIbooqvnpoHnlKjlkIjmiJDoibLntKAgICAgICAgICAgICAgICB8IOasp+ebn+S9v+eUqOaDheWGtSAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICB8IOS4reWbveS9v+eUqOaDheWGtSB8CnwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLXwKfCDmqZnnuqIy5Y+3IChDaXRydXMgUmVkIE5vLjIpICAgICAgfCDnpoHmraLkvb/nlKggICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg56aB5q2i5L2/55SoICAgICB8Cnwg5qmZ6ImyQiAoT3JhbmdlIEIpICAgICAgICAgICAgICAgfCDnpoHmraLkvb/nlKggICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg56aB5q2i5L2/55SoICAgICB8Cnwg5Zu657u/IChGRCZDIEdyZWVuIE5vLjMpICAgICAgICAgfCDnpoHmraLkvb/nlKggICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg56aB5q2i5L2/55SoICAgICB8Cnwg6K+x5oOR57qiIChGRCZDIFJlZCBOby40MCkgICAgICAgIHwg6ZmQ5Yi25L2/55So77yM6ZyA5qCH5rOo4oCc5Y+v6IO95b2x5ZON5YS/56ul5rS75Yqo5LiO5rOo5oSP5Yqb4oCdICAgICAgIHwg6ZmQ5Yi25L2/55SoICAgICB8Cnwg5p+g5qqs6buEIChGRCZDIFllbGxvdyBOby41KSAgICAgIHwg6ZmQ5Yi25L2/55So77yM6ZyA5qCH5rOo4oCc5Y+v6IO95b2x5ZON5YS/56ul5rS75Yqo5LiO5rOo5oSP5Yqb4oCdICAgICAgIHwg6ZmQ5Yi25L2/55SoICAgICB8Cnwg5pel6JC96buEIChGRCZDIFllbGxvdyBOby42KSAgICAgIHwg6ZmQ5Yi25L2/55So77yM6ZyA5qCH5rOo4oCc5Y+v6IO95b2x5ZON5YS/56ul5rS75Yqo5LiO5rOo5oSP5Yqb4oCdICAgICAgIHwg6ZmQ5Yi25L2/55SoICAgICB8Cnwg5Lqu6JOdIChGRCZDIEJsdWUgTm8uMSkgICAgICAgICAgfCDpmZDliLbkvb/nlKggICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg6ZmQ5Yi25L2/55SoICAgICB8Cnwg6Z2b6JOdIChGRCZDIEJsdWUgTm8uMikgICAgICAgICAgfCDpmZDliLbkvb/nlKggICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIHwg6ZmQ5Yi25L2/55SoICAgICB8Cnwg6LWk6JeT57qiIChGRCZDIFJlZCBOby4zKSAgICAgICAgIHwg6ZmQ5Yi25L2/55So77yM5LuF5Y+v55So5LqO6bih5bC+6YWS5qix5qGD44CB57OW5riN5qix5qGDICAgICAgICAgICB8IOmZkOWItuS9v+eUqCAgICAgfAoK6LWE5paZ5p2l5rqQ77yaSUFDTSwgRUZTQSwgRGVlcCBHcmVlbiBQZXJtYWN1bHR1cmUsIEZvb2QgU3RhbmRhcmQgQWdlbmN5LCBHQiAyNzYwLTIwMjQsIOaWueato+ivgeWIuOeglOeptuaJgA==
收藏
行业数据
2026-01-15
原图定位
查看详情
2018-2024各年NMPA及FDA合批准的抗
fCDlubTku70gfCDmipfkvZPoja/mlbDph4/vvIjkuKrvvIkgfAp8LS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwKfCAyMDE4IHwgMjAgICAgICAgICAgICAgICB8CnwgMjAxOSB8IDE2ICAgICAgICAgICAgICAgfAp8IDIwMjAgfCAxNiAgICAgICAgICAgICAgIHwKfCAyMDIxIHwgMjEgICAgICAgICAgICAgICB8CnwgMjAyMiB8IDIxICAgICAgICAgICAgICAgfAp8IDIwMjMgfCAyMyAgICAgICAgICAgICAgIHwKfCAyMDI0IHwgMzIgICAgICAgICAgICAgICB8CgrotYTmlpnmnaXmupDvvJrnmb7lpaXotZvlm77mi5vogqHkuabvvIxGREHvvIxDREXvvIzlvJfoi6Xmlq/nibnmspnliKnmlofvvIzlm73ogZTmsJHnlJ/or4HliLg=
收藏
行业数据
2026-01-05
原图定位
查看详情
2018-2024FDA批准的创新抗体药分类
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
收藏
行业数据
2026-01-05
原图定位
查看详情
最新数据
全球全年龄段奶粉市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球酸奶及发酵乳制品市场规模(亿美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球药用级益生菌市场规模(百万美元)
收藏
行业数据
2026-07-30
原图定位
查看详情
全球益生菌膳食补充剂市场规模及增速
收藏
行业数据
2026-07-30
原图定位
查看详情
全球拥有AKK专利菌株的核心企业
收藏
行业数据
2026-07-30
原图定位
查看详情
药筛及优化技术创新为 first in class药物发现赋能。新药研发,尤其是 First in Class药物的研发的核心在于新靶点的发现。而新靶点的发现必须借助于高通量筛选技术、创新的药物发现技术。根据文献数据表明,近年来 FDA获批的药物中,FIC药物占比逐渐提升。在此过程中,对创新性的新药发现的技术需求巨大,以应对新药研发热潮。
行业数据
原图定位
当前图表所属:
百诚医药-公司首次覆盖报告:综合型CRO 加速转型权益分成业务厚积薄发-230811(30页).pdf
财务报表预测与比率分析
公司部分重点研发管线及进度(截至2022年年报)
公司核心高管信息
公司历史发展沿革
下载图片或Excel,需升级至尊VIP会员或「预见者」VIP
立即去升级
客服
商务合作
小程序
服务号
回到顶部
折叠
微信扫码登录
微信扫码登录
双重福利,扫码领取!
关注公众号『三个皮匠报告』,免费领取报告
1.100+最新优质行业报告
2.每周免费精选报告分享
手机快捷登录
账号登录
记住密码
忘记密码?
验证即登录,未注册将自动创建账号
获取验证码
收不到验证码注意事项
登录代表您已阅读并同意
《三个皮匠服务条款》